Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06210854 · ClinicalTrials.gov registry record · Phase 2
Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT06210854 is a Phase 2 study that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 48 participants.
The verdict
NCT06210854, a Phase 2 study, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This research is being done to test the safety and feasibility of an investigational DNA vaccine called pBI-11 and to find out what effects, if any, it has on women with persistent human papillomavirus 16 (HPV16+) and/or human papillomavirus (HPV18+) cervical infection. The DNA vaccine is designed to promote an immune response to treat disease caused by HPV types 16 and 18, viruses that can cause cervical cancer. The pBI-11 DNA vaccine or a placebo will be administered intramuscularly using the TriGridTM Delivery System.
Interventions
- BIOLOGICAL pBI-11 (3 doses)
- BIOLOGICAL pBI-11 (1 dose)
- BIOLOGICAL Placebo (2 doses)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2026-06-25 |
| Est. Completion | 2029-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06210854
The ClinicalTrials.gov registry entry for NCT06210854 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which pBI-11 (3 doses) is the first listed.
NCT06210854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06210854 about?
NCT06210854 is a clinical study titled "Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+". This research is being done to test the safety and feasibility of an investigational DNA vaccine called pBI-11 and to find out what effects, if any, it has on women with persistent human papillomavirus 16 (HPV16+) and/or human papillomavirus (HPV18+) cervical infection. The DNA vaccine is designed ...
What is the current status of trial NCT06210854?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2026-06-25. Estimated completion is 2029-05.
What interventions are being tested in trial NCT06210854?
The interventions under investigation include: pBI-11 (3 doses) (BIOLOGICAL), pBI-11 (1 dose) (BIOLOGICAL), Placebo (2 doses) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06210854?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.